Abstract
Introduction
Increasing evidence indicates that the development of type 2 diabetes is driven by chronic low grade beta-cell inflammation. However, it is unclear whether pancreatic inflammation can be noninvasively visualized in type 2 diabetes patients. We aimed to assess pancreatic 18 F-FDG uptake in type 2 diabetes patients and controls using 18 F-fluorodeoxylglucose positron emission tomography/computed tomography ( 
Material and methods
In this retrospective cross-sectional study, we enrolled 20 type 2 diabetes patients and 65 controls who had undergone a diagnostic 18 F-FDG PET/CT scan and obtained standardized uptake values (SUVs) of pancreas and muscle. Pancreatic SUV was adjusted for background uptake in muscle and for fasting blood glucose concentrations.
Results
The maximum pancreatic SUVs adjusted for background muscle uptake (SUV max.m ) and fasting blood glucose concentration (SUV glucose ) were significantly higher in diabetes patients compared to controls ( 
Introduction
Hyperglycemia and type 2 diabetes (T2D) are driven by a decline in beta-cell function and mass against a background of insulin resistance [1, 2] . Beta-cell dysfunction is present before diabetes onset [3, 4] and worsens over time, determining the progressive course of the disease [5, 6] . The underlying pathophysiological mechanisms of beta-cell dysfunction are yet to be unraveled. However, increasing evidence indicates that chronic low-grade Langerhans islet inflammation is involved. Several studies have linked increased presence and a pro-inflammatory phenotype of islet macrophages to beta-cell inflammation, dysfunction and apoptosis, likely mediated through secretion of pro-inflammatory cytokines such as interleukin-1β and tumor necrosis factor-α [7] [8] [9] [10] [11] [12] [13] . In keeping with this idea, various anti-inflammatory therapies have been shown to modestly improve beta-cell function in type 2 diabetes patients [14] . Taken together, these lines of evidence suggest a role for islet inflammation in the development of type 2 diabetes. The difficulty in obtaining human pancreatic tissue combined with the limitations of post-mortem assessments, islet cultures and rodent studies, has hampered the study of islet inflammation in diabetes [15] . Thus, noninvasive visualization of pancreatic inflammation would greatly increase insight into the pathogenesis of type 2 diabetes and aid to assess effects of beta-cell-sparing interventions. A well accepted imaging modality for visualization of inflammation is positron emission tomography/computed tomography (PET/CT) with 18 F-fluorodeoxylglucose ( 18 F-FDG) [16] . This technique relies on the fact that activated inflammatory cells have increased glucose metabolism and thereby higher 18 F-FDG uptake than normal cells [17] . For example, it was shown that FDG uptake in carotid arerial wall of diabetes subjects was increased compared to controls [18] . Moreover, 18 F-FDG PET/CT scanning of plaque inflammation has been used to assess efficacy of anti-inflammatory therapy [19] . Here we hypothesized that compared to non-diabetic controls, type 2 diabetes patients have increased pancreatic 18 F-FDG uptake on PET/CTs.
Materials and methods

Study design and patient selection
In this retrospective study, we included patients referred to the Department of Nuclear Medicine of our hospital for a 18 F-FDG PET/CT between January 1 st and July 31 st , 2015. The following data were extracted from electronic medical files: age, sex, height, weight, indication for 18 F-FDG PET/CT, medical history, confirmation of diabetes diagnosis according to ADA criteria, diabetes duration, use of medication and fasting blood glucose concentrations. For this study, a waiver from the local ethical committee (Medisch Ethische Toetsings Commissie AMC) was obtained that stated that no informed consent was needed and data did not have to be fully anonymized, as the data were collected as part of a routine procedure and were not used to guide treatment decisions or influenced planned treatment. Patients were excluded if they met one of the following criteria: age <18 years; fasting blood glucose concentration �7.0 mmol/L on the day of the PET/CT without a medical history of diabetes; acute or chronic pancreatitis or the presence of pancreatic calcifications or cystic lesions; intra-abdominal malignancy; type 1 diabetes; HIV infection; use of oral or i.v. antibiotics in the 6 weeks preceding the PET/CT; use of systemic immunomodulatory drugs in the 2 weeks preceding the PET/ CT; radiotherapy or chemotherapy in the 6 weeks preceding the PET/CT; alcohol abuse, defined as an intake of 5 or more units daily; use of recreational drugs; imaging that did not include the whole pancreas; only low-dose PET/CT available; insufficient imaging or; insufficient available patient data. F-FDG PET/CT images were analyzed using Hybrid Viewer (Hermes Medical Solutions, Stockholm, Sweden). PET images were reconstructed iteratively using ordered-subset expectation maximization software. PET, CT, and fused PET/CT images were available for review and were displayed as non-corrected and attenuation-corrected images in axial, coronal, and sagittal planes. Regions of interest (ROIs) were manually drawn over the tissues of interest on axial views on the CT images on a slice-by-slice basis, so as to cover the entire volume of the pancreas (S1 Fig) or spleen. A circular ROI was also drawn on four consecutive transverse slices of the erector spinae muscle in order to be able to adjust for background uptake of 18 F-FDG. Separate ROIs were merged into a volume of interest. Mean standardized uptake values (SUV mean ) and SUV of the hottest voxel (SUV max ) within the defined regions were automatically generated by the software. The assessor was blinded to the patients' diabetes status. A detailed description of PET/CT acquisition and analysis can be found in the Supporting Information.
Study outcomes
The main outcome was the difference between diabetes patients and controls in SUV max.m , the maximum pancreatic SUV corrected for background uptake in muscle according to the following formula:
As secondary outcomes, we determined SUV glucose , the maximum pancreatic SUV corrected for blood glucose concentration, according to the following formula [20] .
SUV glucose ¼ SUV max pancreas � Fasting blood glucose 7
As a sensitivity analysis, we repeated all analyses using spleen as background: (Fig 1 and S1 Table) . SUV max.m was positively correlated with diabetes presence (r s = 0.30, p = 0.005) and BMI (r s = 0.26, p = 0.016) and negatively correlated with age (r s = -0.23, p = 0.036). SUV glucose was correlated with diabetes presence (r s = 0.43, p<0.001) and BMI (r s = 0.39, p< 0.001), but not with age (r s = -0.06, p = 0.616).
In simple linear regression, diabetes patients had a 0.94 (95%CI 0.28-1.61) higher SUV max.m and a 1.06 (95%CI 0.68-1.45) higher SUV glucose compared to controls, respectively. After Table) . In a sensitivity analysis using spleen as background, the presence of diabetes remained a significant predictor (S1 Table) . We found no significant interaction between diabetes presence and BMI (p = 0.872) or age (p = 0.131).
Discussion
To our knowledge, this is the first study to show that type 2 diabetes patients have significantly increased background-corrected pancreatic 18 F-FDG uptake compared to non-diabetic controls. This association persisted after adjustment for BMI and age as well as after correction for prevailing glucose concentrations. Our study is in line with previous evidence that suggest an important role for beta-cell inflammation in T2D development. In addition, this study suggests that pancreatic inflammation-possibly reflecting islet inflammation-can be imaged in vivo and paves the way for prospective studies that investigate the role of inflammation on beta-cell function and diabetes development over time and modulating effects of anti-inflammatory therapies.
As beta-cell function starts to decline years before the clinical diagnosis of T2D [21] , islet inflammation may be most prominent in early diabetes. Considering the patients in our study had on average been diagnosed with diabetes for approximately 7 years and that diabetes onset occurs 4-8 years before clinical diagnosis [22] , it is possible that a study in patients with a more recent-onset diabetes would reveal an even greater difference between diabetes patients and controls. However, the relatively small sample size of 20 diabetes patients in our study precluded such an analysis.
Previously, Honka et al. assessed pancreatic 18 F-FDG uptake in 25 morbidly obese subjects and found no difference between patients with and without T2D [23] . However, in that study 18 F-FDG uptake was not adjusted for background uptake nor fasting plasma glucose concentrations, despite the inverse correlation between 18 F-FDG uptake and fasting plasma glucose concentrations that was reported. Moreover, the patients included in the study of Honka et al. had severe pancreatic steatosis, raising the possibility that 18 F-FDG uptake was mainly mediated by adipocytes instead of islets.
Our retrospective study has several limitations. First, even though 18 F-FDG PET/CT is widely used to image inflammation, glucose uptake could also be indicative of metabolic activity rather than inflammation. As such, beta cells stressed by chronic hyperglycemia could have higher metabolic activity. Thus, even though islets of T2D patients largely fail the capacity to meet the increased insulin demand, this technique may not be specific enough to distinguish inflammation. Second, destruction of beta cells could lead to further decreased metabolic activity and lower 18 F-FDG uptake compared to controls, resulting in an underestimation of the PET/CT signal in T2D subjects. Unfortunately, we did not have information on plasma insulin concentrations as a marker of beta cell activity. Thirdly, the Langerhans islet only take up a small portion of the pancreas. As such, the PET/CT signal within the pancreas may reflect exocrine pancreatic tissue. Nevertheless, in a non-obese diabetic mouse model FDG uptake was shown to be 2-3 times higher in islets that were infiltrated by immune cells than in remaining pancreas [24] . Thus, assuming several islets within one voxel may be infiltrated, the increased maximum 18 F-FDG signal in the diabetes subjects is in line with previous data. Finally, most participants in this study underwent PET-CT scanning for diagnosis or followup of malignancy. Although indications for scanning in the control group were similar to the diabetes group and patients with pancreatitis or intra-abdominal malignancies were excluded from the study, we cannot rule out that the state of inflammation in a diabetes population without (suspected) malignancy may be different.
In order to overcome the limitations of our study design, we used various methods to analyze pancreatic 18 F-FDG uptake. First, we corrected pancreatic 18 F-FDG uptake to background muscle uptake. Previously, increases in plasma glucose levels were associated with a significant increase in muscle uptake of 18 F-FDG, despite the fact that endogenous glucose can competitively inhibit 18 F-FDG uptake [25] [26] [27] [28] . Thus, even though we feel that correction for background glucose uptake is necessary, correcting for 18 F-FDG uptake in muscle may have led to an underestimation of background-corrected pancreatic signal in the diabetes patients. After using muscle as background tissue, we performed a sensitivity analysis using spleen as background and found similar results. This suggests that the impact of possible confounding factors is most likely limited. Finally, we used multivariate regression analysis to adjust for age and BMI, as age was significantly correlated with SUV max.m and BMI was significantly different between the groups. Nevertheless, our findings should be confirmed in a prospective setting.
In conclusion, we showed that pancreatic 18 F-FDG uptake, when adjusted for background uptake, is increased in type 2 diabetes patients, independent of BMI and age. Moreover, we showed that 18 F-FDG PET/CT might be a viable tool for in vivo visualization of pancreatic inflammation in diabetes. The possibility of in vivo imaging of pancreatic inflammation offers a promising novel way to gain more insight in the processes underlying beta cell dysfunction in type 2 diabetes in prospective and intervention studies. 
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